Ignyta (RXDX) Appoints Valerie Harding As Senior Vice President, Chemistry, Manufacturing, And Controls

SAN DIEGO--(BUSINESS WIRE)--Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, announced today that Valerie Harding, Ph.D., has been appointed to the newly-created role of Senior Vice President, Chemistry, Manufacturing, and Controls.

"We are fortunate to add Val to our executive team at this point in the growth of our company," said Jonathan Lim, M.D., Chairman and CEO of Ignyta. "Val's rich experience in pharmaceutical drug development and formulation, cultivated over more than 25 years at Pfizer, will be indispensable to us as we advance our commercialization plans for entrectinib and continue the development of the rest of our pipeline for the benefit of cancer patients."

Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.